MAP2K1 and cancer: Here, the MEK1/MEK2 inhibitors all ranked in the top six (five out of the top six ranking inhibitors), revealing that cancers that were more dependent on functional MAPK pathway genes were likely to exhibit stronger responses to MEK1/MEK2 inhibitors than cancers that were less dependent on functional MAPK pathway genes.